Here is a collection of cancer patients who used an alternative route to heal their cancers.
A replacement therapy called GcMAF, which is undergoing pre-clinical trials worldwide, has been proven to eradicate stage-4 cancer. Symptoms have either improved or been completely eradicated in around 85% of the 700 people who had cancers ranging from breast, liver and prostate to bladder and ovarian cancer.
Results have been most successful in patients who have followed a strict no-sugar diet along with a high intake of vitamin D3, largely derived from the sun.
GcMAF, which stands for Gc-protein-derived Macrophage Activating Factor, was discovered in 1990 by Japanese scientist Dr Yamamoto who found that all healthy humans have natural GcMAF and it kickstarts the immune system to fight disease.
20 years later, biomedical company Immuno Biotech has made GcMAF available as a replacement therapy. Its scientists initially produced First Immune GcMAF and have since developed a more potent protein, GOleic, which takes the GcMAF molecule and combines it with Oleic acid and Vitamin D.
GcMAF has been the subject of intense scientific research in recent years. More than 60 peer-reviewed research papers have been produced by 154 scientists who have trialled it on a range of viral and neurological conditions, such as advanced cancer, autism, chronic fatigue syndrome and the rare disorder LMBBS.
Scientists at Immuno Biotech published 16 peer-reviewed papers in 2013. These have appeared in OncoImmunology, Frontiers in Neuroscience and Nutrients, where a paper about GcMAF and cancer cell apoptosis reached the top 5% most-read scientific papers of all time.
Scientific director of Immuno Biotech, Marco Ruggiero, has worked with cancer for 30 years and is now having success with an advanced ultrasonography technique to target tumours directly with GcMAF. Ruggiero, also a medical doctor, says: “GcMAF is not a drug but an essential component of our body, just like insulin. When we are unable to produce these essential components, a number of diseases arise. All these diseases can be reverted by administration of the missing component. In my opinion, the importance of GcMAF derives from this consideration. It is a physiologic protein that is essential for a very large number of functions in our body.”
Video of GcMAF at work
How to Kill Cancer Cells with 90% Less Toxicity than Chemo – Dr. Murray Susser, MD
Here is a booklet you can download from http://elementalwellnesscenter.com
I found it quite informative and an easy tool to show to friends and family about our medicine.
María M. Caffarel 1, Clara Andradas, Eduardo Pérez-Gómez, Manuel Guzmán, Cristina Sánchez ⇑
Breast cancer is a very common disease that affects approximately 1 in 10 women at some point in their lives. Importantly, breast cancer cannot be considered a single disease as it is characterized by distinct pathological and molecular subtypes that are treated with different therapies and have diverse clinical outcomes. Although some highly successful treatments have been developed, certain breast tumors are resistant to conventional therapies and a considerable number of them relapse. Therefore, new strategies are urgently needed, and the challenge for the future will most likely be the development of individualized therapies that specifically target each patient’s tumor. Experimental evidence accumulated during the last decade supports that cannabinoids, the active components of Cannabis sativa and their derivatives, possess anticancer activity. Thus, these compounds exert anti-proliferative, pro-apoptotic, antimigratory and anti-invasive actions in a wide spectrum of cancer cells in culture. Moreover, tumor growth, angiogenesis and metastasis are hampered by cannabinoids in xenograft-based and genetically-engineered mouse models of cancer. This review summarizes our current knowledge on the antitumor potential of cannabinoids in breast cancer, which suggests that cannabinoid-based medicines may be useful for the treatment of most breast tumor subtypes.